Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dorzagliatin in Type 2 Diabetes Mellitus
NCT06263348Phase 4Completed
- Sponsor
- Hua Medicine
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dorzagliatin in type 2 diabetes mellitus (T2DM), sponsored by Hua Medicine. Primary endpoint: Incidences of Adverse Drug Reactions and Serious Adverse Events at 52 weeks. Started Jan 2024; status: completed.
02
Drugs
dorzagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06263348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06263348.